In vivo whole-body resting energy expenditure and insulin action in human malignant hyperthermia.
BACKGROUND
Malignant hyperthermia (MH) is a pharmacogenetic disease triggered by volatile anesthetics or succinylcholine. The disorder is heterogenetic and caused by abnormal calcium regulation within skeletal muscle cells. No clear metabolic differences have been found in MH-susceptible (MHS) persons in vivo while not having MH episodes, but some reported signs suggest that insulin action and energy turnover might be altered in muscle of MHS persons.


METHODS
In fasting and insulin-stimulated conditions, using the glucose clamp technique and indirect calorimetry, we assessed in vivo resting energy expenditure (REE) and nutrient utilization rates in 10 MHS, 5 MH-equivocal (MHE) and 10 MH-negative (MHN) persons from 14 families. With a model using the persons' fat-free mass, fat mass, age, and gender, we calculated their predicted REE and compared it with measured REE in 10 MHS and 10 MHN persons (measured - predicted = residual REE).


RESULTS
In vivo measured REE and glucose disposal rates were similar in 10 MHS and 10 MHN persons. Only during insulin stimulation was residual REE greater in MHS persons (6.4%; P = 0. 013).


CONCLUSIONS
In vivo insulin action is unimpaired in MHS persons. Although the absolute values of whole-body REE are the same in MHS and MHN persons, the part of REE independent of the determinants fat-free mass, fat mass, age, and gender is moderately greater in MHS than in MHN persons during insulin exposure. This suggests that MH susceptibility might influence insulin-stimulated energy turnover in muscle.
Freymond
D
D
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Daniel.Freymond@chuv.hospvd.ch
Dériaz
O
O
Frascarolo
P
P
Reiz
S
S
Jéquier
E
E
Urwyler
A
A
D000328:Adult; D018685:Anesthetics, Inhalation / Q000494:pharmacology; D001481:Basal Metabolism; D001823:Body Composition; D002110:Caffeine / Q000494:pharmacology; D002153:Calorimetry, Indirect; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D005215:Fasting / Q000378:metabolism; D005260:Female; D005947:Glucose / Q000378:metabolism*; D006221:Halothane / Q000494:pharmacology; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D016014:Linear Models; D008297:Male; D008305:Malignant Hyperthermia / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D018408:Patch-Clamp Techniques
D018685:Anesthetics, Inhalation; D000697:Central Nervous System Stimulants; D007328:Insulin; D002110:Caffeine; D005947:Glucose; D006221:Halothane